Neofytou Kyriakos, Giakoustidis Alexandros, Mudan Satvinder
Department of Academic Surgery, Royal Marsden Hospital, Fulham Road, London, UK.
J BUON. 2015 May-Jun;20(3):746-55.
The discovery of prognostic factors for patients who undergo hepatectomy for colorectal liver metastases (CRLM) in the era of neoadjuvant chemotherapy is imperative. This study aimed to establish a simple, cheap and easily available prognostic score for these patients.
Preoperative carcinoembryonic antigen (CEA), serum alkaline phosphatase (ALP), and lymphocyte count (LC) were used for the establishment of a prognostic score (CALy PS). The cut-off levels of these variables were determined by applying receiver operating curve (ROC) analysis. The final prognostic score assigned one risk point for each variable (CEA>4 μg/L, ALP>93 U/L, and LC≥1.6x10(9)/L).
One hundred and thirty-five patients were included. Two risk categories were established with 0-1 and 2-3 points, respectively. CALy 0-1 vs CALy 2-3, and CALy 2-3 were associated with decreased disease free survival (DFS) and overall survival (OS) both in univariate and multivariate analysis (DFS: HR 1.84; 95% CI 1.18-2.86; p=0.007; OS: HR 2.25; 95% CI 1.23-4.11; p=0.008). When four risk categories were established with 0,1,2,and 3 points,CALy was again associated with decreased DFS and OS both in univariate and in multivariate analysis (DFS: HR 1.37; 95% CI 1.083-1.74; p=0.009; OS:HR 1.84; 95% CI 1.31-2.59; p<0.001). Three-year DFS rates for these categories (CALy 0, CALy 1, CALy 2, and CALy 3) were 45, 38, 15 and 7%, respectively, and the 5-year OS rates were 78, 68, 32, and 24%, respectively.
This simple, cheap, and easily available risk score provides good prognostic accuracy for both DFS and OS for patients undergoing liver resection for liver-only colorectal metastases after neoadjuvant chemotherapy.
在新辅助化疗时代,发现接受肝切除术治疗结直肠癌肝转移(CRLM)患者的预后因素势在必行。本研究旨在为这些患者建立一个简单、廉价且易于获得的预后评分系统。
术前癌胚抗原(CEA)、血清碱性磷酸酶(ALP)和淋巴细胞计数(LC)用于建立预后评分(CALy PS)。通过应用受试者工作特征曲线(ROC)分析确定这些变量的临界值。最终的预后评分是每个变量(CEA>4μg/L、ALP>93 U/L和LC≥1.6x10⁹/L)赋予一个风险点。
纳入135例患者。建立了两个风险类别,分别为0 - 1分和2 - 3分。在单因素和多因素分析中,CALy 0 - 1与CALy 2 - 3以及CALy 2 - 3均与无病生存期(DFS)和总生存期(OS)降低相关(DFS:HR 1.84;95% CI 1.18 - 2.86;p = 0.007;OS:HR 2.25;95% CI 1.23 - 4.11;p = 0.008)。当建立0、1、2和3分的四个风险类别时,CALy在单因素和多因素分析中再次与DFS和OS降低相关(DFS:HR 1.37;95% CI 1.083 - 1.74;p = 0.009;OS:HR 1.84;95% CI 1.31 - 2.59;p < 0.001)。这些类别(CALy 0、CALy 1、CALy 2和CALy 3)的三年DFS率分别为45%、38%、15%和7%,五年OS率分别为78%、68%、32%和24%。
这个简单、廉价且易于获得的风险评分系统对于新辅助化疗后仅肝转移的结直肠癌患者接受肝切除术后的DFS和OS具有良好的预后预测准确性。